|
Post by _neil on Feb 2, 2015 16:27:30 GMT -5
I was wondering since SNY is a French company, they might see it as an advantage with the Euro poised to get weaker. Does that translate to any benefit to MNKD or will be a straight USD in sales, USD in sharing before SNY exchanges it for Euros? I am not implying this will be material to the share price or valuation of MNKD but just checking if other members have given it any thought..
|
|
|
Post by bobw on Feb 2, 2015 18:05:51 GMT -5
Right now, as I see it, expenses are mostly in dollars and revenue is all in dollars.
|
|
|
Post by mnholdem on Feb 3, 2015 19:02:35 GMT -5
Since U.S. sales will be handled by Sanofi U.S. and expenses come out of sales revenue, I would think there is no need to bring money in from overseas...not until we launch in Europe anyway.
|
|